Partnership at BioAsia 2024 underscores commitment to fostering innovation in healthcare and biotechnology
Joint efforts to introduce cutting-edge RNA therapeutics to India’s pharmaceutical landscape
Queensland based Southern RNA, a leading Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid manufacturing, including DNA and mRNA, is excited to announce a strategic partnership with DKSH, a leading Market Expansion Services provider, in India. This partnership marks a significant milestone in Southern RNA’s expansion strategies and highlights the burgeoning relationship between the Australian and Indian biotechnology sectors.
The partnership, supported by Trade Investment Queensland (TIQ), the dedicated business agency of the Government of Queensland, perfectly aligns with the state’s initiatives to boost local exporters and attract investment and was unveiled at the recently concluded BioAsia 2024 conference.
“The collaboration between Southern RNA and DKSH signifies a significant leap forward in enhancing the burgeoning relationship between Queensland and India, particularly in the realms of healthcare and biotechnology,” highlighted Mr. Abhinav Bhatia, Senior Trade Commissioner at Trade and Investment Queensland. “This partnership not only fosters economic growth and innovation but also facilitates the exchange of expertise and resources between the two regions, and we look forward to more such collaborations in this critical sector.”
Through this partnership both Southern RNA and DKSH will foster innovation and growth in the life sciences industry by leveraging DKSH’s extensive network and expertise in the Asia Pacific region to introduce Southern RNA’s cutting-edge products and services to India’s dynamic pharmaceutical landscape.
Australia, long recognized for its mining and agriculture sectors, has rapidly emerged as a center for biomanufacturing excellence, particularly in the realm of RNA therapeutics. The successful efforts of the Australian Federal government in attracting industry giants like Moderna, along with the Queensland government’s initiative to attract Sanofi to the state, reflect Australia’s conducive economic environment and supportive landscape for biotechnology innovation. Southern RNA, established amidst this favorable backdrop and supported by a federal grant, embodies the Australian spirit of pioneering in the biomanufacturing sector.
“This partnership with DKSH is not just a business expansion for Southern RNA; it’s a bridge between Australia and India in the realm of biotechnology and pharmaceuticals,” said Garry Heaney, Chief Operating Officer, at Southern RNA. “By entering the Indian market, we are not only looking to extend our reach but also to contribute to the global health ecosystem by providing access to our advanced RNA therapeutics and manufacturing capabilities.“
India, renowned as a global pharmaceutical powerhouse, presents strategic partnership opportunities and a vast market for Southern RNA’s innovative products and services. The collaboration with DKSH is poised to set a precedent for future Australia-India business relations, particularly in the high-growth biotech sector.
